Fennec Pharmaceuticals (NASDAQ:FENC) Versus Candel Therapeutics (NASDAQ:CADL) Critical Comparison
Fennec Pharmaceuticals (NASDAQ:FENC) Versus Candel Therapeutics (NASDAQ:CADL) Critical Comparison
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) and Candel Therapeutics (NASDAQ:CADL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Fennec PharmPharmticals(纳斯达克代码：FENC-GET Rating)和Candel Treateutics(纳斯达克代码：CADL-GET Rating)都是小盘医疗公司，但哪一家更好？我们将根据这两家公司的估值、分析师建议、收益、盈利能力、机构所有权、股息和风险的强弱对它们进行比较。
Institutional & Insider Ownership
机构与内部人持股
43.3% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.1% of Candel Therapeutics shares are owned by institutional investors. 9.4% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 44.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fennec PharmPharmticals 43.3%的股份由机构投资者持有。相比之下，Candel Treateutics 21.1%的股份由机构投资者持有。Fennec PharmPharmticals 9.4%的股份由内部人士持有。相比之下，Candel Treateutics 44.3%的股份由内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一只股票有望实现长期增长。
Volatility and Risk
波动性和风险
Fennec Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Fennec PharmPharmticals的贝塔系数为0.03，表明其股价的波动性比标准普尔500指数低97%。相比之下，Candel Treateutics的贝塔系数为0.1，这表明其股价的波动性比标准普尔500指数低90%。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Fennec Pharmaceuticals | N/A | -214.78% | -97.25% |
| Candel Therapeutics | N/A | -20.18% | -13.13% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 芬内克制药公司 | 不适用 | -214.78% | -97.25% |
| 秋茄治疗公司 | 不适用 | -20.18% | -13.13% |
Valuation and Earnings
估值和收益
This table compares Fennec Pharmaceuticals and Candel Therapeutics' gross revenue, earnings per share (EPS) and valuation.
此表比较了Fennec制药公司和Candel治疗公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fennec Pharmaceuticals | $170,000.00 | 1,483.88 | -$17.35 million | ($0.82) | -11.71 |
| Candel Therapeutics | $130,000.00 | 397.85 | -$36.12 million | ($0.42) | -4.26 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 芬内克制药公司 | $170,000.00 | 1,483.88 | -1,735万美元 | ($0.82) | -11.71 |
| 秋茄治疗公司 | $130,000.00 | 397.85 | -3,612万元 | ($0.42) | -4.26 |
Fennec Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fennec制药公司的收入和收益高于Candel治疗公司。Fennec制药公司的市盈率低于Candel治疗公司，这表明它目前是两只股票中更负担得起的一只。
Analyst Recommendations
分析师建议
This is a summary of current recommendations and price targets for Fennec Pharmaceuticals and Candel Therapeutics, as provided by MarketBeat.com.
这是由MarketBeat.com提供的Fennec制药公司和Candel治疗公司的当前建议和目标价的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fennec Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| Candel Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 芬内克制药公司 | 0 | 0 | 5 | 0 | 3.00 |
| 秋茄治疗公司 | 0 | 0 | 3 | 0 | 3.00 |
Fennec Pharmaceuticals presently has a consensus price target of $14.83, indicating a potential upside of 54.51%. Candel Therapeutics has a consensus price target of $10.33, indicating a potential upside of 477.28%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Fennec Pharmaceuticals.
Fennec制药公司目前的共识目标价为14.83美元，表明潜在上行空间为54.51%。Candel治疗公司的共识目标价为10.33美元，这表明潜在的上涨幅度为477.28。鉴于Candel治疗公司更有可能上行，分析人士显然认为Candel治疗公司比Fennec制药公司更有利。
Summary
摘要
Candel Therapeutics beats Fennec Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Candel Treeutics在两只股票比较的11个因素中有6个击败了Fennec PharmPharmticals。
About Fennec Pharmaceuticals
关于Fennec制药公司
(Get Rating)
(获取评级)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
生物制药公司Fennec PharmPharmticals Inc.开发用于美国癌症治疗的候选产品。它的主要候选产品是硫代硫酸钠，已经完成了预防顺铂引起的儿童听力损失或耳毒性的第三阶段临床试验。该公司前身为Adherex Technologies Inc.，2014年9月更名为Fennec PharmPharmticals Inc.。Fennec制药公司成立于1996年，总部设在北卡罗来纳州的研究三角公园。
About Candel Therapeutics
关于秋茄治疗公司
(Get Rating)
(获取评级)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel治疗公司是一家临床阶段的生物制药公司，致力于为癌症患者开发免疫疗法。该公司开发了CAN-2409，目前正处于治疗胰腺癌的第二阶段临床试验；治疗前列腺癌的第三阶段临床试验；以及治疗肺癌的第二阶段临床试验，以及治疗高级别胶质瘤的Ib/II阶段临床试验。它还开发了CAN-3110，这是一种治疗复发胶质母细胞瘤的I期临床试验。它还开发了启迪发现平台，这是一个系统的、基于HSV的迭代发现平台，利用人类生物学和先进的分析来为实体肿瘤创造新的病毒免疫疗法。该公司前身为Advantagene，Inc.，并于2020年11月更名为Candel治疗公司。该公司成立于2003年，总部设在马萨诸塞州的尼达姆。
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Fennec PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Fennec制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。